GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Eighteen participants using GLP-1 medications enrolled in the study, ten of which experienced gastrointestinal symptoms and were administered Relesium. Initial results are promising, showing that ...

The GLP-1 RA cohort had significantly lower odds of developing early-onset colorectal cancer (0.4 vs 0.7%) vs the no GLP-1 RA cohort. HealthDay News — Glucagon-like peptide-1 receptor agonists ...

PanTheryx®, a global nutrition and biotechnology company, today announced the launch of Relesium ™, a patented, all-natural supplement formulated to address pervasive gut-related side effects ...

all-natural supplement formulated to address pervasive gut-related side effects of glucagon-like peptide 1 (GLP-1) medications, including popular weight-loss drugs like Ozempic ®, Wegovy ®, Mounjaro ® ...